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ABSTRACT A novel KPC variant, KPC-41, was identiﬁed in a Klebsiella pneumoniae
clinical isolate from Switzerland. This -lactamase possessed a 3-amino-acid insertion
(Pro-Asn-Lys) located between amino acids 269 and 270 compared to the KPC-3
amino acid sequence. Cloning and expression of the blaKPC-41 gene in Escherichia
coli, followed by determination of MIC values and kinetic parameters, showed that
KPC-41, compared to those of KPC-3, has an increased afﬁnity to ceftazidime and a
decreased sensitivity to avibactam, leading to resistance to ceftazidime-avibactam
once produced in K. pneumoniae. Furthermore, KPC-41 exhibited a drastic decrease
of its carbapenemase activity. This report highlights that a diversity of KPC variants
conferring resistance to ceftazidime-avibactam already circulate in Europe.
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As part of the antibiotic resistance crisis, carbapenemase-producing Enterobacterales(CPE) are among the main concerns. Indeed, apart from their resistance to almost
all -lactams, including carbapenems, which is observed most of the time, they are
frequently coresistant to other antibiotic families (1). The main carbapenemases iden-
tiﬁed worldwide are the serine carbapenemases of the KPC and OXA-48 types, and the
metallo--lactamases (MBLs) of the NDM, VIM, and IMP types (1). Development of novel
drugs is mostly driven by the spread of those determinants. Among the recently
developed drugs, combinations of -lactams and -lactamases inhibitors, such as
ceftazidime-avibactam (CZA) and ceftolozane-tazobactam, are very successful alterna-
tives (2). Although serine -lactamases are inhibited by avibactam (AVI), this combina-
tion is not active against MBLs (2). Despite a still limited use of CZA at a worldwide
scale, KPC variants resistant to AVI have been already reported (3–9). Such resistance is
mostly driven by amino acid substitutions in the sequence of the KPC carbapenemase
that might be selected after a CZA treatment (22). Variants conferring CZA resistance
are derivatives of either KPC-2 or KPC-3 enzymes. Substitutions in the omega loop
(amino acid positions 164 to 179) have been often associated with concomitant
enhanced afﬁnity toward ceftazidime and prevention of binding to AVI (7–10).
Here we describe -lactamase KPC-41, a variant of KPC-3 conferring resistance to
CZA. This novel KPC variant possesses a 3-amino-acid insertion in its protein sequence
compared to KPC-3 and has been identiﬁed from a Klebsiella pneumoniae clinical
isolate.
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which should be cited to refer to this work.
RESULTS AND DISCUSSION
K. pneumoniae strains FF and UM were recovered from rectal swabs of a 72-year-old
man with pancreatic cancer, hospitalized at the University Hospital Center of Lausanne,
Switzerland. Actually, this patient was living and previously hospitalized in Sicily before
his transfer with a known history of a ciproﬂoxacin-containing treatment for cholangitis.
At his admission in Switzerland, he screened positive for a KPC-3-positive K. pneu-
moniae strain (isolate FF). After pancreatic surgery performed in Switzerland, he was
treated with piperacillin-tazobactam. Following a peritonitis episode, colistin (loading
dose of 3 g, followed by 1.5 g/12 h) for 28 days and CZA (2/0.5 g for 5 days followed
by 1/0.25g/8h for 19 days) were administered (Fig. 1). Then systematic rectal screenings
identiﬁed another K. pneumoniae strain (isolate UM) (see below). Finally, this patient
developed a cholangitis episode as a result of a biliary stent occlusion. He was treated
successfully with colistin (one loading dose of 3 g followed by 3 g/day) for 10 days and
meropenem (2 g/8 h) for 12 days (Fig. 1).
K. pneumoniae isolate UM was resistant to expanded-spectrum cephalosporins,
ertapenem, CZA, and aztreonam and remained susceptible to imipenem and mero-
penem (Table 1). This isolate remained susceptible to colistin according to the negative
result of the rapid polymyxin test (data not shown). Carbapenemase activity was
assessed according to the results of the rapid Carba NP test, which was positive for both
K. pneumoniae FF and K. pneumoniae UM isolates. Hence, common procedures to
screen for carbapenem-resistant isolates and to detect any carbapenemase activity
allowed the identiﬁcation of K. pneumoniae UM.
Analysis of the whole-genome sequences of both isolates ruled out any clonal
relationship. Isolate FF belonged to sequence type 307 (ST307), while isolate UM
belonged to ST395. The antibiotic resistome of K. pneumoniae isolate UM included
genes encoding -lactamases TEM-1, SHV, and CMY.
Immediately after the isolation of isolate UM, it was found to be positive for blaKPC
by PCR. Sequencing of the amplicon revealed a KPC variant possessing a 3-amino-acid
insertion (Ambler 269-ProAsnLys-270) within a KPC-3 sequence, leading to a novel
variant named KPC-41.
In order to evaluate the differences in term of hydrolysis spectra between KPC-41
and KPC-3, the corresponding genes were cloned and expressed in Escherichia coli
TOP10. Once produced in this E. coli background, KPC-3 conferred resistance to all
-lactams, including ceftazidime, but it remained susceptible to CZA. On the other
hand, KPC-41 conferred resistance to ceftazidime, reduced susceptibility to expanded-
spectrum cephalosporins such as cefotaxime and cefepime, and yielded only a slight
reduction in the susceptibility to carbapenems (Table 1). Noticeably, this recombinant
E. coli strain producing KPC-41 was resistant to CZA (Table 1).
Some KPC variants conferring CZA resistance have been previously reported, exhi-
FIG 1 Timetable of antimicrobial treatments and isolation of the K. pneumoniae strains FF and UM. Black
bars represent antimicrobial treatments, with numbers representing treatment length in days (d) or the
loading dose (ld). Gray arrows indicate the dates of isolation of K. pneumoniae isolates FF and UM.
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biting a single amino acid substitution often occurring in the omega loop, in particular
at position Ambler 179 (8). In contrast, the amino acid insertion identiﬁed in KPC-41 was
distantly located from the omega loop. Nevertheless, amino acid substitutions distantly
located from the omega loop but leading to resistance to CZA have been also reported
among KPC variants, such as KPC-8 (Val240Gly and His274Tyr) (6) and KPC-23
(Val240Ala and His274Tyr) (11).
The blaKPC-41-positive K. pneumoniae UM belonged to ST395, although the previ-
ously reported KPC producers exhibiting CZA resistance belonged to ST258 (6), ST307
(3), and ST1519 (11). It is noteworthy that an outbreak caused by a KPC-3-producing K.
pneumoniae ST395 isolate (susceptibility to CZA not reported) has been reported in a
neonatal intensive care unit in Palermo, Italy, and in our study the patient carrying K.
pneumoniae UM also originated from Sicily (12).
Mating-out experiments performed with K. pneumoniae UM and using E. coli as a
recipient (23) were successful and conﬁrmed the plasmid location of the blaKPC-41 gene.
Analysis of the corresponding plasmid revealed it was ca. 70 kb and belonged to the
IncFII-type incompatibility group.
Puriﬁcation of both KPC-3 and KPC-41 enzymes was performed, reaching a purity
estimated to be 90%, with a single dominant band on the SDS-polyacrylamide gel for
each protein (data not shown). Kinetic data showed that KPC-41 has a lower hydrolysis
activity of cefotaxime, aztreonam, and imipenem than that of KPC-3 (Table 2). Similar
decreased hydrolytic efﬁciencies for carbapenems of some KPC variants have previously
been reported, such as for the Asp179Tyr KPC-2 mutant (10). In contrast, MIC values of
aztreonam for KPC-41 and KPC-3 remained similar, as previously observed for the
Thr243Ala KPC-3 variant (13).
Kinetic analyses measuring the hydrolysis of ceftazidime were conducted for KPC-3
and KPC-41 enzymes. Although signiﬁcant hydrolysis was detected with KPC-3, no
hydrolysis could be detected with puriﬁed KPC-41 under normal conditions (measure-
ment made over 5 min); however, by performing the assay for 1 h, ceftazidime
hydrolysis was detected with KPC-41, but the hydrolysis rate was much lower than that
of KPC-3 (Fig. 2A).
Considering that KPC-41 conferred signiﬁcant resistance to ceftazidime once pro-
TABLE 1MICs of -lactams for K. pneumoniae clinical isolates, E. coli TOP10 transformants,
and E. coli TOP10 recipient strains
-Lactama
MIC (g/ml)
K. pneumoniae E. coli
UM
(KPC-41)
FF
(KPC-3)
TOP10
(pTOPO-KPC-41)
TOP10
(pTOPO-KPC-3) TOP10
Amoxicillin 128 128 128 128 8
Amoxicillin  CLA 128 128 128 128 8
Ticarcillin 128 128 128 128 4
Ticarcillin  CLA 128 128 128 128 4
Piperacillin 128 128 128 128 2
Piperacillin  TZB 128 128 128 128 2
Cephalothin 128 128 128 128 16
Cefotaxime 32 128 16 128 0.125
Ceftazidime 1,024 1,024 2,048 2,048 0.25
Ceftazidime  AVI 128 4 128 2 0.25
Ceftaroline 256 256 256 256 0.25
Cefepime 16 128 16 128 0.125
Ceftolozane  TZB 256 64 256 256 0.06
Cefoxitin 32 32 8 128 8
Aztreonam 128 128 64 64 0.125
Imipenem 4 8 2 32 0.25
Meropenem 1 8 0.5 16 0.5
Ertapenem 4 16 0.5 32 0.12
aClavulanic acid (CLA) was added at a ﬁxed of 2 g/ml, tazobactam (TZB) at 4 g/ml, and avibactam at
4 g/ml.
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duced by the recombinant E. coli clone, it was therefore speculated that KPC-41 could
strongly bind to ceftazidime but without efﬁcient hydrolysis. Therefore, the afﬁnities of
KPC-3 and KPC-41 for ceftazidime were measured using various concentrations of
ceftazidime, to inhibit the hydrolysis of a reporter substrate (nitroceﬁn). At the same
ceftazidime concentrations, a higher level of inhibition of nitroceﬁn was observed in the
presence of KPC-41 than in the presence of KPC-3 (Fig. 2B and C), and the Ki of
ceftazidime was found to be 3-fold lower for KPC-41 than for KPC-3. Decreased
ceftazidime hydrolysis and increased ceftazidime afﬁnity have been also observed for
the KPC-2 Asp179Asn variant conferring resistance to CZA (7).
Comparative inhibitory activities of clavulanic acid, tazobactam, and AVI were
determined for KPC-41 and KPC-3 (Table 3). The inhibitory activity of AVI toward KPC-41
was much lower than toward KPC-3, while conversely, those of tazobactam and
clavulanic acid were similar toward KPC-41 and KPC-3. An increased inhibitory activity
of the -lactamase inhibitor clavulanic acid, whose structure is basically very different
from that of AVI but is more related to that of tazobactam, has been also reported for
the Asp179Tyr mutant of KPC-2 (10).
Together, these results indicate that the 269-ProAsnLys-270 insertion observed in
TABLE 2 Kinetic parameters of puriﬁed -lactamases KPC-41 and KPC-3a
-Lactam
KPC-41 KPC-3
kcat (s1) Km (M)
kcat/Km
(mM1·s1) kcat (s1) Km (M)
kcat/Km
(mM1·s1)
Benzylpenicillin 5.07 36 0.15 5.6 33 0.2
Cephalothin 4.75 102 0.03 47 113.5 0.4
Cefotaxime 1 116.7 0.008 34.9 532.8 0.065
Ceftazidime ND ND ND 3.3 700 4.7 E3
Aztreonam 1.9 190.16 0.01 5 194.8 0.03
Imipenem 0.17 43.8 0.004 4.7 71.5 0.07
Meropenem ND ND ND 0.47 18.5 0.03
Ertapenem ND ND ND 0.58 37 0.02
akcat, turnover; Km, Michaelis constant (afﬁnity); kcat/Km, speciﬁcity constant (hydrolysis). ND, not determinable
due to a low initial rate of hydrolysis.
FIG 2 Analysis of ceftazidime hydrolysis. (A) KPC-41 and KPC-3 (1 M enzyme) hydrolysis of 25 M ceftazidime (CAZ) at room temperature. (B and C)
Competitive inhibition curves determined with 50 M nitroceﬁn and increasing concentrations of CAZ with 0.1 M KPC-41(B) and 0.1 M KPC-3 (C) at room
temperature. For panels B and C, nitroceﬁn absorbance was measured.
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the KPC-41 sequence was responsible for reduced hydrolysis of cephalothin, cefo-
taxime, and imipenem, associated with a higher afﬁnity toward ceftazidime and with a
reduced sensitivity to AVI. It is noteworthy that KPC-3 differs from KPC-2 by one amino
acid substitution at position 273 that confers already a ca. 30-fold increase of hydrolytic
efﬁciency towards ceftazidime (14).
Conclusion. We report here a multidrug-resistant K. pneumoniae isolate producing
KPC-41, a novel KPC variant conferring resistance to CZA. This is the ﬁrst report of a K.
pneumoniae isolate exhibiting such a resistance pattern in Switzerland. The patient had
been treated with CZA. Several reports of KPC variants conferring CZA resistance
originate from Italy, and the ST395 background of the KPC-41-producing strain has
been shown to be widespread in some Italian hospitals. Therefore, it might be specu-
lated that this Italian patient, hospitalized in Sicily, had been colonized there by K.
pneumoniae producing KPC-41 and that the further treatment with CZA given in
Switzerland likely contributed to its selection.
From a therapeutic point of view, full or partial recovery of susceptibility to carba-
penems observed in such a KPC variant may be considered good news. In the present
case, a therapeutic combination of meropenem and colistin was successful. Use of
meropenem may be justiﬁed by the in vitro data of reversion of KPC-3 mutations
leading to CZA resistance after serial passages of cultures with meropenem (15). We
may also consider double-carbapenem therapy (ertapenem and meropenem, for ex-
ample) as suggested for treating carbapenemase producers in Enterobacterales (16).
Finally, the report underlines that such an isolate can be recovered by routine screening
of carbapenem-resistant strains (at least by using the SuperCarba CHROMagar me-
dium), since the isolate remained resistant to ertapenem, and subsequently by identi-
ﬁcation of the carbapenemase activity by using a biochemical test such as the rapid
Carba NP test.
MATERIALS AND METHODS
Clinical strains and genome analyses. The National Reference Center for Emerging Antibiotic
Resistance (NARA; Fribourg, Switzerland) received K. pneumoniae isolates FF and UM. The genetic
similarity of the K. pneumoniae isolates was evaluated by whole-genome sequencing using both the
Illumina and Nanopore technologies. DNA was extracted with the Wizard Genomic DNA puriﬁcation kit
(Promega; A1120) and libraries were prepared with FC-131-1096 NexteraVRXT. Divergency between the
two strains was evaluated by mapping (bwa 0.7.17) reads of K. pneumoniae UM on the assembled
(Spades 3.11.1) genome of K. pneumoniae FF. Variant calling was performed with GATK’s HaplotypeCaller.
Only genotype calls with 10 reads or supported by 75% of the observations were retained.
Conjugation experiments. Mating-out assays were performed using K. pneumoniae UM as the
donor and E. coli J53 (azide resistant) as the recipient. Selection was made using Trypticase-soy plates
supplemented with amoxicillin (100 g/ml) and sodium azide (100 g/ml). Typing of plasmids was
performed as described previously (17).
Cloning and sequencing. The blaKPC-3 and blaKPC-41 genes were ampliﬁed from DNA of the K.
pneumoniae FF and UM isolates using primers KPC-3-all-Fw (5=-TATATGAATTCAAGGGCGGCTGAAGGAA
TAC-3=) and KPC-3-all-Rev (5=-ATATAGAATTCCGCCATCGTCAGTGCTCTAC-3=). PCR products were cloned
into pCR-BluntII-Topo (Invitrogen, Thermo Fisher). Recombinant plasmids were further transformed into
E. coli strain TOP10. Sequencing of the amplicons and recombinant plasmids was performed by the
company Microsynth (Balgach, Switzerland).
Carbapenemase activity and antimicrobial susceptibility testing. Carbapenemase activity was
detected by using the rapid Carba NP test (18). MIC determinations were performed in triplicate by the
broth microdilution method in Mueller-Hinton broth (Bio-Rad, Marnes-La-Coquette, France), with the
exception of the combinations CZA and ceftolozane-tazobactam, for which MICs were determined by
TABLE 3 Inhibitory concentrations and kinetic inhibition parameters of -lactamase
inhibitors against KPC-41 and KPC-3a
Inhibitor
IC50 (M) Ki (M)
KPC-41 KPC-3 KPC-41 KPC-3
Clavulanic acid 15 20 10 20
Tazobactam 20 50 3 10
Avibactam 6 1 4 1
aIC50 represents the concentration of a drug that is required for 50% inhibition of the enzymatic activity. Ki
corresponds to a relative koff/kon to the inhibitor for the enzyme.
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Etest (AB bioMérieux, Solna, Sweden). Results were interpreted according to EUCAST breakpoints (19).
The CZA resistance breakpoint is deﬁned as 8 g/ml for Enterobacterales. MICs of -lactams were
determined alone or in combination with a ﬁxed concentration of clavulanic acid (2 g/ml), tazobactam
(4 g/ml), or AVI (4 g/ml). The antimicrobial agents were obtained from standard laboratory powders
and were used immediately after their solubilization. The agents and their sources were as follows:
amoxicillin, piperacillin, cefepime, cephalothin, ceftazidime, and clavulanic acid, Sigma (Saint-Quentin
Falavier, France); ticarcillin and cefoxitin, ROTH (Arlesheim, Switzerland); benzylpenicillin and tazobactam,
Abcam (Cambridge, UK); cefotaxime, aztreonam, and ertapenem, Acros Organic (Geel, Belgium); imi-
penem, Carbosynth (Berkshire, UK), meropenem, Combi-Blocks (San Diego, CA); AVI, MedChem Express
(Luzern, Switzerland); and ceftolozane, ACS DOBFAR (Tribiano, Italy). Susceptibility to colistin was
evaluated by using the rapid polymyxin NP test (20).
Screening of carbapenem-resistant Gram negatives was performed by using mSuperCARBA plates
(CHROMagar, Paris, France).
-Lactamase puriﬁcation and relative molecular mass determination. Cultures of E. coli TOP10
harboring plasmid pTOPO-KPC-3 and pTOPO-KPC-41 were grown overnight at 37°C in 2 liters of Luria
broth with kanamycin (50 g/ml). The bacterial suspensions were pelleted, resuspended in 20 ml of
50 mM morpholine ethanesulfonic acid (MES) buffer (pH 5.5), disrupted by sonication, and centrifuged
at 11,000 g for 1 h at 4°C. The enzyme extract was loaded onto a preequilibrated HiTrap Q HP column
(GE Healthcare) with MES buffer. The resulting enzyme extract was recovered in the ﬂowthrough and was
then eluted with a linear NaCl gradient (0 to 1 M). The fractions showing the highest -lactamase activity
were pooled and dialyzed against 100 mM phosphate buffer (pH 7.0), prior to a 10-fold concentration
with a Vivaspin 20 (GE Healthcare). The puriﬁed -lactamase extract was immediately used for enzymatic
determinations. To assess the relative purity of the extracts and to determine the molecular weight of the
KPC-3 and KPC-41 -lactamases, puriﬁed enzymes were subjected to SDS-PAGE analysis. Enzyme extracts
and marker proteins were boiled for 10 min in a 1% SDS–3% -mercaptoethanol solution before being
separated by electrophoresis (100 V for 1 h) at room temperature. In parallel, molecular weights were
determined in silico using the Compute pI/Mw tool on the Expasy server (21).
Kinetic measurements. Puriﬁed -lactamases were used for kinetic measurements (Km and kcat),
performed at 30°C in 100 mM sodium phosphate (pH 7.0). A Genesys 10S UV-visible (UV-Vis) spectro-
photometer (Thermo Scientiﬁc) was used to determine the initial rates of hydrolysis. The following
wavelengths and absorption coefﬁcients () were used: for benzylpenicillin, 232 nm and 1,100
M1 cm1; for cephalothin, 62 nm and –7,960 M1 cm1; for ceftazidime, 260 nm and –8,660 M1 cm1;
for cefotaxime, 265 nm and –6,260 M1 cm1; for imipenem, 297 nm and –9,210 M1 cm1; for mero-
penem, 298 nm and –10,940 M1 cm1; and for aztreonam, 318 nm and –640 M1 cm1.
Determination of enzyme parameters (Km and kcat) was unsuccessful for ceftazidime because of the
low level of hydrolysis. For this reason, to analyze ceftazidime hydrolysis, the antibiotic was incubated
with 1 M KPC-3 or KPC-41 enzyme and hydrolysis was measured for 1 h, as reported previously (9). To
compare the afﬁnities of ceftazidime for KPC-3 and for KPC-41, we performed competitive inhibition of
50 M nitroceﬁn using 0.1 M KPC-3 or 0.1 M KPC-41 and various concentration of ceftazidime, as
reported previously (7).
The 50% inhibitory concentrations (IC50) were determined for clavulanic acid, tazobactam, and AVI for
each enzyme. Various concentrations of these inhibitors were preincubated with the puriﬁed enzyme for
5 min at 30°C to determine the concentrations that reduced the hydrolysis rate of 100 M cephalothin
by 50%. The results are expressed in micromolar units. The total protein content was measured by
Bradford assay.
The Ki value was determined by direct competition assays using 100 M cephalothin. Inverse initial
steady-state velocities (1/V0) were plotted against the inhibitor concentration ([I]) to obtain a straight
line. The plots were linear and provided y-intercept and slope values used for Ki determination. Ki was
determined by dividing the value for the y-intercept by the slope of the line and then corrected by taking
into account the cephalothin afﬁnity by the following equation: Ki (corrected)  Ki (observed)/(1 
[S]/Km). Here, “[S]” is the concentration of cephalothin (100 M) used in the assay and Km is the Michaelis
constant determined for cephalothin (102 M for KPC-41 and 113.5 M for KPC-3). IC50 and Ki values
were determined in triplicate.
Accession number(s). Genome sequences were deposited at EMBL/EBI under EBI project
PRJEB33694. The sequence of KPC-41 was deposited in the NCBI database under GenBank accession
number MK497255.
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